Publicacións (14) Publicacións de Gema Molina Arriero

2024

  1. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort

    Gastroenterologia y Hepatologia

  2. Implementation of a Teledermatology Electronic Consultation Program to Improve the Care of Patients with Inflammatory Bowel Disease

    Telemedicine Reports, Vol. 5, Núm. 1, pp. 12-17

  3. Long-Term Evaluation of Intensified Ustekinumab in Crohn's Disease: Real-Life Results

    JOURNAL OF CROHNS & COLITIS, Vol. 18, Núm. Supl 1, pp. I1039

2023

  1. Should Inflammatory Bowel Disease Clinicians Provide Their Patients with e-Health Resources? Patients' and Professionals' Perspectives

    Telemedicine journal and e-health : the official journal of the American Telemedicine Association, Vol. 29, Núm. 10, pp. 1504-1513

2022

  1. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  2. TELEIBD: A telematic fast-track pathway for patients with high suspicion of Inflammatory Bowel Disease in primary care

    JOURNAL OF CROHNS & COLITIS, Vol. 16, Núm. Supl 1, pp. I314-I315

  3. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Colonic ulcer as an uncommon finding of mastocytosis

    Gastroenterologia y Hepatologia, Vol. 44, Núm. 5, pp. 380-381

  2. Effectiveness of ustekinumab in fistulising perianal Crohn′s disease refractory or intolerant to anti-TNF

    Journal of Crohn's and Colitis, Vol. 15, Núm. Supplement_1, pp. S419-S420

  3. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19

2020

  1. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease

    United European Gastroenterology Journal, Vol. 8, Núm. 9, pp. 1056-1066

2019

  1. Letter: double‐dose intensification – a quick way to reverse antibody formation and loss of response in patients treated with adalimumab

    Alimentary Pharmacology & Therapeutics, Vol. 49, Núm. 6, pp. 821-822

2018

  1. Epidemiology of NAFLD/NASH and potential impact in our health area

    Fatty liver disease: a reality with many questions (Eolas), pp. 45-62

2017

  1. Pseudopoliposis colónica en enfermedad inflamatoria intestinal

    Gastroenterologia y Hepatologia